1,4-DIHYDROPYRIDINES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTITHROMBOTIC DRUGS

Abstract: The present invention refers to 1,4-dihydropyridi­ nes,to processes for their preparation and to their use as antithrom­ botic drugs. Said new 1,4-dihydropyridines have the following general formula (I) wherein R represents hydrogen or a saturated or unsaturated alkyl group, with a linear or branched chain of 1 to 8 carbon atoms, R¹ represents an alkyl radical with a linear, branched or cyclic, saturated or unsaturated chain of 1 to 12 carbon atoms, which may be interrupted by an oxygen or by a 2-(N-salicylamido)ethyl group, n is a number equal to 1 or 2. These 1,4-dihydropyridines are obtained by processes based on the Hantzch reaction or on modifications thereof.

Description: The invention relates to 1,4 dihydropyridines, having an exceptional blood platelet aggregation activity and lacking any effect on the heart and vascular smooth muscle, processes for their preparation and their use as antithrombotic drugs. Said 1,4-dihydropyridine having the following general formula: wherein R is hydrogen or a saturated or unsaturated alkyl group with a linear or branched chain of 1 to 8 carbon atoms R¹ is an alkyl radical with a linear, branched or cyclic, saturated or unsaturated chain of 1 to 12 carbon atoms which may be interrupted by an oxygen or by a 2-(N-salicylamido)ethyl group n is a number equal to 1 or 2. Nowadays, there is no doubt about the role of platelets in arterial thrombosis (J.M. Sullivan in "Blood platelet function and medicinal chemistry," page 1, Elsevier Biomedical, New York (1984)) and that their main activation processes: adhesion, aggregation and releasing reaction, are fundamental factors in the pathogenesis of thromboembolic disorders, which are one of the most important causes of death in the western world. The build-up of a platelet aggregate at a damaged area of a blood vessel wall is a primary event in the development of a thrombus. Circulating thromboemboli may appear when these thrombi become emboli or when platelets find aggregating agents in the stream. A drug capable of directly or indirectly inhibiting these processes would have an obvious interest in the therapeutic control of those pathologic situations wherein platelets are involved and the use thereof would be very useful in the prophylaxis and treatment of arterial thrombosis. A plurality of 1,4-dihydropyridine derivatives having pharmacologic activities such as, fundamentally, antihypertensive and vasodilative activities are known in the art which in some cases may be combined with thromboxane synthetase, calmoduline, phosphodiesterase and platelet aggregation activities. Furthermore, some benzisothiazolone derivants having platelet aggregation inhibitory activities have been described. Thus, WO-A-84/02132 described molecules of the general formula: wherein X is a substituted aromatic ring and wherein Y situated in the lateral chain at position 3 of the ring can be a N atom belonging to an amidic group or to the piperazine cycle. This molecule is described as having antihypertnesive activity. EP-A-0164010 described 1,4-dihyropyridines of the general formula: wherein thee is a substituted phenyl group at position 4 of the ring and a NO₂ group at position 5 so that the classical structure of 1,4-dihydropyridines with two carboxylate groups in positions 3 and 5 disappears. Said compounds are described as having positive inotropic (calcium agonistic) activities. EP-A-0128010 describes 1,4-dihydropyridine compounds of the general formula having a substituted benzene ring at position 4 of the 1,4-dihydropyridine ring and a lateral linear or branched lateral chain including a non-heterocyclic N atom, at position 3. Said compounds are described as having antihylertensive action and long duration thereof. EP-A-0145434 describes 1,4-dihydropyridine compounds of the general formula wherein R³ is always a substituted phenyl group and wherein within the lateral chain at position 3 of the ring there can be a N atom belonging to an alkyl amine, a piperazine ring or a pyrinidine ring. Said compounds are described as having principally hypotensive and coronary vasodilative activities although these may be combined with inhibitory effects with respect to phosphodiesterase, calmoduline and platelet aggregation. EP-A-0172029 describes compounds of the general formula: wherein thre is always an aromatic group at position 4 of the 1,4-dihyropyridine ring, and an imidazole group within the lateral chain at position 4 of the ring. Said compounds are described as having antihypertensive and antithrombotic activities. EP-A-0173126 describes a compound having the basic structure of 1,4-dihydropyridine of the general formula wherein there is also a substituted phenyl group at position 4 of the 1,4-dihyropyridine ring although it has no N atom within the lateral chain at position 3 of the ring. Said compounds are described as having coronary vasodilative and hypotensive effects as their main activities although these may be combined with activities relative to prophylaxis and treatment of thrombosis. EP-A-000254 described a 2-[gamma-(1-piperidinyl) propyl]-1,2-benzisothiazol-3-one of the general formula having a platelet aggregation inhibitory activity. DE-A-2652201 describes benzisothiazolones of the general formula also having platelet aggregation inhibitory effects. As all described 1,4-dihyropyridine compounds do have an effect on the heart and vascular smooth muscle which isn some case case be combined with secondary effects as antithrombotic effects based on thromboxane synthetase, calmoduline and phosphodiesterase inhibitions, their therapeutical administrability only for platelet aggregation inhibition is inconveniently low as there would be cardiovascular secondary effects as, for example, hypotension, bradicardia and cardiac failures, etc. Benzisothiazolone compounds of the above-mentioned type have proved to be highly toxic, according to their own inventors (K.H. Baggaley et al., J. Med. Chem., 28, 1661-67 (1985.)) The present invetion as claimed is intended to remedy these disadvantages by providing 1,4-dihydropyridine compounds of the general formula wherein R is a hydrogen or a saturated or unsaturated alkyl group, with a linear or branched chain of 1-8 carbon atoms; R¹ is an alkyl radical with a linear, branched or cyclic, saturated or unsaturated chain of 1-12 carbon atoms, which may be interrupted by an oxygen or by a 2-(N-salicylamido) ethyl group; n is a number equal to 1 or 2; These compounds have an alkyl group at position 4, and a heterocyclical group of the type 1,2-benzisothiazolon-3-one, 1,1-dioxide linked to the carboxylate at position 3 of the 1,4-dihydropyridine ring through an alkylene bridge by the N atom, which structure has not been described in the prior art. Such 1,4-dihydropyridine compounds show an exceptional blood platelet aggregation inhibitory activity and, surprisingly, no effects on the cardiovascular system. They are not toxic at therapeutic doses and are stable. The new compounds may be obtained according to methods based on the Hantzch reaction or on modifications thereof, such as indicated hereinafter: a) A compound of formula (II) wherein R and n are as previously defined, is made to react with a compound of formula (III) wherein R¹ has been previously defined, so as to yield a compound of formula (I); or b) A compound of formula (IV) wherein n has been previously defined, is made to react with a compound of formula (V) wherein R and R¹ have been previously defined, so as to yield a compound of formula I, or c) A compound of formula (VI) CH₃-CO-CH₂-COOR¹ (VI) wherein R¹ has been previously defined, is made to react with a compound of formula (IV), wherein n has been previously defined and a compound of formula (VII) R-CHO (VII) wherein R has been previously defined, so as to yield a compound of formula (I), or d) A compound of formula (VIII) wherein n has been previously defined, is made to react with a compound of formula (III), wherein R¹ has been previously defined, and a compound of formula (VII), wherein R has been previously defined, so as to yield a compound of formula (I), or e) A compound of formula (VI), wherein R¹ has been previously defined, is made to react with a compound of formula (VIII), wherein n has been previously defined, and a compound of formula (VII), wherein R has been previously defined, and with NH₃, so as to yield a compound of formula (I). The present invention also includes the formation of stable salts of compounds of formula I with organic or inorganic, pharmacologically suitable acids. The reaction conditions used in a) and e) variants are as follows: Water is considered as solvent, as well as all inert organic solvents such as alcohols, e.g. methanol, ethanol, isopropanol and n-butanol; ethers, such as inferior dialkyl ethers, e.g. diethyl ether, ter-buthylmethyl ether or cyclic ethers such as tetrahydrofurane and dioxane; inferior aliphatic carboxylic acids such as acetic and propionic acids; inferior dialkylformamides such as dimethylformamide; inferior alkylnitriles such as acetonitrile; dimethylsulfoxide; liquid heteroaromatic bases, such as pyridine. Solvent mixtures, water included, may also be used. If necessary, the reagents may be made to react without solvents. The reaction temperature may vary between 20 and 150°C, preferably between 50 and 100°C. The reaction is usually carried out at the boiling temperature of the solvent used. The reaction may be conducted at the normal pressure, but also under high pressure. It is usually conducted at the normal pressure. The time of the reaction ranges from 45 minutes to 10 hours. According to the invention, the separation and isolation of the product yielded along the reaction are carried out by techniques usually used for this purpose, the product being able to be submitted to a conventional purification such as recrystallization, distillation or chromatography. The present invention is illustrated by the following examples: EXAMPLE 1 2- {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)} ethyl 2,6-dimethyl-5-ethoxycarbonyl-4-methyl-1,4-dihydropyridine-3-carboxylate. A) 2- {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)} -ethyl acetylacetate. 10.1 ml (11.1 g; 0.13 mol) of Diketene are slowly added, under agitation, onto a mixture comprising 30 g (0.13 mol) of N-(2-hydroxyethyl)-1,2-benzisothiazol-3(2H)one-1,1-dioxide and 0.2 ml of triethylamine previously heated to about 80°C. The addition speed is adjusted so that the reaction temperature stays between 85 and 90°C. Once the addition is finished, the reaction mixture is kept under agitation at 90°C for 3 hours. After said period of time, the resulting solution is diluted with 500 ml of CH₂Cl₂, washed with H₂O (2 x 500 ml), decolorized by passing it through Active Carbon-Infusoria Earth and dried over anhydrous Na₂SO₄. Finally, the evaporation of the solvent under low pressure leads to an oily yellow liquid that solidifies slowly as to yield finally a crystalline white solid with melting point: 62-3°C (ethanol recrystallization). The reaction yield is 88%. I.R. Spectrum (NaCl) ν(cm⁻¹): 2980, 1770, 1740, 1720, 1460, 1420, 1330, 1260, 1190, 1150, 1050, 1000, 960, 750, 670, 610. M.N.R. Spectrum (CDCl₃) p.p.m.: 7.8 (4H,m); 4.5 (2H,t); 4 (2H,t); 3.5 (2H,s); 2.2 (3H,s). B) 2- {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)} ethyl 2,6-dimethyl-5-ethoxycarbonyl-4-methyl-1,4-dihydropyridine-3-carboxilate. A mixture comprising 13.05 g (0.04 mol) of 2- {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)} ethyl acetylacetate, 5.41 g (0.04 mol) of ethyl 3-aminocrotonate and 2.4 ml (1.85 g; 0.04 mol) of acetaldehyde in 50 ml of ethanol, is heated under reflux with agitation for 10 hours. After cooling to -10°C the resulting solution, a light yellow solid with melting point: 144-6°C (ethyl acetate recrystallization) is obtained. The reaction yield is 81%. Analysis for C₂₁H₂₄N₂O₇S: %C %H %N Calculated 56.24 5.39 6.25 Found 55.96 5.54 5.98 I.R. Spectrum (KBr): ν(cm⁻¹): 3400, 3130, 2980, 2940, 1750, 1700 1620, 1480, 1450, 1340, 1330, 1300, 1280, 1220, 1180, 1100, 1060, 1000, 830, 790, 770, 750, 680, 610. M.N.R. Spectrum (δ, DMSO-D₆): p.p.m.: 8.5 (1H,sa); 8 (4H,m); 4.6 to 3.6 (7H,m); 2.2 (6H,s); 1.2 (3H,t); 0.9 (3H,d). EXAMPLE 2 2- {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)} ethyl 2,6-dimethyl-4-methyl-5-methoxycarbonyl-1,4-dihydropyridine-3-carboxylate. A mixture comprising 15 g (0.05 mol) of 2 {N-(1,2-benzisothiazolyl-3(2H) one-1,1-dioxide)} ethyl acetylacetate (obtained according to the process given in example 1), 5.55 g (0.05 mol) of methyl 3-aminocrotonate and 2.7 ml (2.12 g; 0.05 mol) of acetaldehyde in 50 ml of ethanol is heated under reflux with agitation for 10 hours. After evaporation of the solvent under low pressure, the resulting residue is solved into 15 ml of ethyl acetate under boiling and this solution is cooled to 5°C. A yellowish solid with melting point: 146-9°C (ethyl acetate recrystallisation) is thus obtained. The reaction yield is 58%. Analysis for C₂₀H₂₂N₂O₇S %C %H %N %S Calculated 55.29 5.10 6.45 7.38 Found 55.06 5.25 6.34 7.18 I.R. Spectrum (KBr): ν(cm⁻¹): 3380, 3100, 3030, 2960, 1750, 1700, 1670, 1500, 1450, 1430, 1330, 1260, 1220, 1180, 1140, 1090, 1060, 770, 750, 670. M.N.R. Spectrum (δ, CDCl₃ + DMSO-D₆): p.p.m.: 8.2 (1H,sa); 7.9 (4H,m); 4.4 (2H,td); 4.1 (3H,td); 3.6 (3H,s); 2.2 (6H,s); 0.8 (3H.d). EXAMPLE 3 2 {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)} ethyl 2,6-dimethyl-4-methyl-1,4-dihydropyridine-5-carboxylate. A mixture comprising 15 g (0.05 mol) of 2- {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)} ethyl acetylacetate (obtained according to the process described in example 1), 12.73 g (0.05 mol) of 2-(N-salicylamido)ethyl 3-aminocrotonate and 2.7 ml (2.12 g; 0.05 mol) of acetaldehyde in 50 ml of ethanol, is heated under reflux with agitation for 10 hours. After the evaporation of the solvent under low pressure, the resulting residue is solved into 10 ml of ethanol under boiling and this solution is cooled to -10°C. A slightly yellow solid with melting point: 86-90°C is thus obtained. The reaction yield is 46%. Analysis for C₂₈H₂₉N₃O₉S %C %H %N %S Calculated 57.63 5.01 7.20 5.49 Found 57.42 5.12 6.94 5.23 I.R. Spectrum (KBr) ν(cm⁻¹): 3380, 3100, 2980, 1750, 1700, 1650, 1610, 1560, 1500, 1350, 1310, 1220, 1200, 1150, 1110, 1070, 780, 760, 680. M.N.R. Spectrum (δ, DMSO-D₆): p.p.m.: 12.3 (1H,sa); 8.8 (1H,m); 8.6 (1H,m); 8.6 to 6.8 (8H,m); 4.7 to 3.6 (9H,m); 2.3 (6H,s); 1(3H, sda). EXAMPLE 4 {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)} methyl 2,6-dimethyl-4-methyl-5-methoxycarbonyl-1,4-dihydropyridine-3-carboxylate. A) {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)} methyl acetylacetate. 55.5 ml (60.9 g; 0.72 mol) of diketene are slowly added, with agitation, onto a suspension consisting of 128.69 g (0.60 mol) of N-hydroxymethyl-1,2-benzisothiazol-3(2H)one-1,1-dioxde and 9.66 g (0.03 mol) of mercuric acetate in 138 ml of acetic acid. Once the addition is finished, the resulting mixture is kept with agitation at room temperature for 8 hours and then it stands resting overnight. The resulting solid is filtered, washed with H₂O and dried, thereby obtaining a white product with melting point: 111-3°C. The reaction yield is 89%. I.R. Spectrum (KBr): ν(cm⁻¹): 3100, 3040, 1770, 1760, 1730, 1600, 1430, 1420, 1340, 1240, 1190, 1140, 1040, 1010, 970, 800, 750, 680, 650, 610. M.N.R. Spectrum (δ, CDCl₃ + DMSO-D₆): p.p.m.: 8 (4H,m); 5.8 (2H,s); 3.6 (2H,s); 2.2 (3H,s). B) {N-(1,2- benzisothiazolyl-3(2H)one-1,1-dioxide)}methyl 2,6 dimethyl-4-methyl-5-methoxycarbonyl-1,4-dihydropyridine-3-carboxylate. A mixture comprising 15 g (0.05 mol) of {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)}methyl acetylacetate, 5.81 g (0.05 mol) of methyl 3-aminocrotonate and 3 ml (2.22 g; 0.05 mol) of acetaldehyde in 50 ml of ethanol is heated under reflux with agitation for 8 hours. After said period of time is over, the resulting solution is cooled to -10°C, thereby obtaining a yellow solid with melting point: 89-92°C (ethanol recrystallization). The reaction yield is 58%. Analysis for C₁₉H₂₀N₂O₇S . C₂H₆O: % C % H % N % S Calculated 54.07 5.62 6.00 6.87 Found 53.87 5.49 6.20 6.78 I.R. Spectrum (KBr): ν(cm⁻¹): 3460, 3400, 3120, 3000, 1760, 1700, 1660, 1500, 1440, 1390, 1350, 1260, 1220, 1190, 1140, 1100, 1030, 1000, 770, 750, 680. M.N.R. Spectrum (δ, CDCl₃): p.p.m.: 7.9 (4H,m); 6.9 (1H,s); 5.9 (2H,s); 3.7 (6H,m+s); 2.8 (1H,s); 2.3 (6H,s); 1.3 to 0.8 (3H + 3H, t+d). EXAMPLE 5 {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)} methyl 2,6-dimethyl-5-ethoxycarbonyl-4-methyl-1,4-dihydropyridine-3-carboxylate. A mixture comprising 15 g (0.05 mol) of {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)}methyl acetylacetate (obtained according to the process given in example 4), 6.52 g (0.05 mol) of acetaldehyde in 50 ml of ethanol is heated under reflux for 8 hours. Once said period of time is over, the resulting solution is cooled to -10°C, thereby obtaining a solid with melting point: 162-4°C (ethyl acetate and aqueous ethanol recrystallization). The reaction yield is 40%. Analysis for C₂₀H₂₂N₂O₇S: % C % H % N % S Calculated 55.30 5.10 6.45 7.38 Found 55.00 5.12 6.47 7.55 I.R. Spectrum (KBr): ν(cm⁻¹): 3380, 2960, 1770, 1710, 1680, 1490, 1350, 1290, 1260, 1220, 1200, 1140, 1070, 1030, 770, 750, 680. M.N.R. Spectrum (δ, DCCl₃): p.p.m.: 7.9 (4H,m); 6.6 (1H, sa); 5.9 (2H,s); 4.3 to 3.6 (2H + 1H, 2c); 2.3 (6H,s); 1.3 (3H,t); 1 (3H,d). EXAMPLE 6 2- {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)} ethyl 4-n-butyl-2,6-dimethyl-5-methoxycarbonyl-1,4-dihydropyridine-3-carboxylate. A mixture comprising 20 g (0.06 mol) of 2- {N-(1,2-benzisothiazolyl-3(2H)one-1,1-dioxide)}ethyl acetylacetate (obtained according to the process given in example 1), 7.40 g (0.06 mol) of methyl 3-aminocrotonate and 6.9 ml (5.53 g; 0,06 mol) of valeraldehyde in 65 ml of ethanol, is heated under reflux with agitation for 10 hours. After said time is over, the solvent is evaporated under low pressure and the resulting residue is solved into 25 ml of ethyl acetate under boiling and cooled at room temperature. A light yellow solid is thus obtained, with melting point: 119-121°C (ethyl acetate recrystallization). The reaction yield is 68%. I.R. Spectrum (KBr): ν(cm⁻¹): 3340, 3100, 2960, 2920, 1740, 1710, 1660, 1490, 1450, 1350, 1270, 1220, 1190, 1140, 1090, 1010, 970, 790, 770, 760, 740, 670, 610. M.N.R. Spectrum (δ, DMSO-D₆): p.p.m.: 8.5 (1H,sa); 8.2 to 7.8 (4H,m); 4.4 to 3.3 (5H + 3H, m+s); 2.2 (6H,s); 1.2 to 0.5 (9H,m). The antiplatelet activity of the described compounds was measured by an "in-vitro" activity assay and an "in-vivo" thrombosis model in the mouse, which are indicated hereinafter. A) "IN-VITRO" AGGREGATION ON HUMAN PLATELETS (Born, G.V.R., Nature 194 :927 (1962)). Citrated human blood was used, from which platelet-rich plasma (PRP) was prepared. 450 ul PRP aliquots were incubated at 37°C with the assayed compounds at a single concentration of 10⁻⁴M for 15 minutes. Aggregating agents (2ug/ml collagen and 2.5 uM ADP) were added in a 50 ul volume and the aggregation was measured as optical density decrease in the platelet suspension. Simultaneously to the collagen aggregation, the effect on the releasing reaction that measures the ATP secretion from activated platelets was determined (Feinman, R.D., Lubowsky, J., Charo, I.F., Zabinski, M.P.; J. Lab. Clin. Med. 90 :125 (1977)). The results are expressed in Table 1. B) "IN VIVO" THROMBOSIS MODEL (DiMinno, G., Silver, M.J.; J. Pharmacol. Exptl. Ther. 225 :57 (1983)). This is a suitable method for the screening of antithrombotic agents having a primary activity on platelet thormboembolism. CD-l Charles River male mice weighing 30 g were used. They received an i.v. injection of 15 ug collagen and 1.8 ug epinephrine in 100 ul of isotonic saline solution. About the 90% of the animals died or were paralysed for more than 15 minutes. Drugs were intraperitoneally administered as a suspension in 0.5% C.M.C. and the protecting effect thereof against thrombosis was measured one to four hours after the administration. The results are expressed in Table 2. EFFECT OF THE COMPOUNDS ON HUMAN PRP "IN VITRO" AGGREGATION AND RELEASING REACTION. INHIBITION % Compound according to example No. ADP Collagen Releasing Reaction 1 12 84 80 2 20 48 43 3 15 24 18 4 5 14 19 5 20 55 51 6 8 15 29 DIPYRIDAMOL 17 21 38 Compound according to Example No. Protection % 30 mg/kg 60 mg/kg 1 50 70 2 0 42 3 62 62 4 20 20 5 30 50 6 12 34 DIPYRIDAMOL 30 30

Claims: 1,4-dihydropyridines useful as antithrombotic drugs having an exceptional activity as platelet activation inhibitors, at the same time as they lack any activigy on heart and vascular smooth muscle, said new 1,4-dihydropyridines being characterized by having the following formula (I): wherein, R represents hydrogen or a saturated or unsaturated alkyl group with a linear or branched chain of 1 to 8 carbon atoms, R¹ represents an alkyl radical with a linear, branched or cyclic, saturated or unsaturated chain of 1 to 12 carbon atoms, which may be interrupted by an oxygen atom, or a 2-(N-salicylamido)ethyl group, n is a number equal to 1 or 2. 1,4-dihydropyridines, according to claim 1, characterized in that the different radicals of formula (I) have the following meanings: (a) R = methyl, R¹ = ethyl and n = 2; (b) R = methyl, R¹ = methyl and n = 2; (c) R = methyl, R¹ = 2-(N-salicylamido)ethyl and n = 2; (d) R = methyl, R¹ = methyl and n = 1; (e) R = methyl, R¹ = ethyl and n = 1; (f) R = n-butyl, R¹ = methyl and n = 2. A process for the preparation of 1,4-dihydropyridines as described in claim 1, characterized in that: a) A compound of formula (II) wherein R and n are as previously defined, is made to react with a compound of formula (III) wherein R¹ is as previously defined, so as to yield a compound of formula (I); b) A compound of formula (IV) wherein n is as previously defined, is made to react with a compound of formula (V) wherein R and R¹ are as previously defined, so as to yield a compound of formula (I); c) A compound of formula (VI) CH₃-CO-CH₂-COOR¹ (VI) wherein R¹ is as previously defined, is made to react with a compound of formula (IV), wherein n is as previously defined and a compound of formula (VII) R-CHO (VII) wherein R is as previously defined, so as to yield a compound of formula (I); d) A compound of formula (VIII) wherein n is as previously defined, is made to react with a compound of formula (III), wherein R¹ is as previously defined, and a compound of formula (VII), wherein R is as previously defined, so as to yield a compound of formula (I); e) A compound of formula (VI), wherein R¹ is as previously defined, is made to react with a compound of formula (VIII), wherein n is as previously defined and with a compound of formula (VII), wherein R is as previously defined and with NH₃, so as to yield a compound of formula (I). Drugs to be used in the preventive and curative treatment of thrombosis, characterized by containing at least a compound of the formula (I), according to claim 1. Drugs according to claim 4, characterized by containing non-toxic excipients, acceptable from the pharmacological point of view.

Inventors: CILLERO, JAVIER, DORREGO, FERNANDO, FAU DE CASA-JUANA, MIGUEL, ORTEGA, PILAR, PRIEGO, JAIME, SUNKEL, CARLOS
Applicants: ALTER, S.A.
Application year: 1987
Main classification: C07D417
IPC codes: A61K31, C07D211, C07D417, A61P7